29 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Feb 22
Current report (foreign)
4:01pm
statements regarding our future financial condition, results of operations, business strategy and plans, prospective products, product approvals, anticipated … condition, results of operations, business strategy and financial needs. These forward-looking statements are inherently subject to a number of risks
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
10 Jun 22
Current report (foreign)
6:05am
statements regarding our future financial condition, results of operations, business strategy and plans, prospective products and their potential benefits … that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
5 Jun 23
Current report (foreign)
4:28pm
financial condition, results of operations, business strategy and plans, prospective products and their potential benefits, product approvals … of operations, business strategy and financial needs. These forward-looking statements are inherently subject to a number of risks, uncertainties
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
30 Dec 22
Connect Biopharma Provides Business and Clinical Development Program Update
8:00am
strategy, and particularly in the potential of our lead product candidate, CBP-201, which is currently in development to treat atopic dermatitis
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
1 Jun 23
Current report (foreign)
4:24pm
upon discontinuation and high potency, there is an opportunity to optimize the dosing strategy in future trials to further enhance the already
20-F
EX-4.10
7xsyw
31 Mar 22
Annual report (foreign)
4:33pm
UPLOAD
a3r5k 5qslvvh0
13 Jan 21
Letter from SEC
12:00am
6-K
EX-99.3
7iulk
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.2
6spk1f9
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.1
8u6fwi72y3z19 izuct
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
DRSLTR
pxs1xx7g71cl9
26 Jan 21
Correspondence regarding draft registration statement
12:00am
6-K
EX-99.2
g4s19xfkfzj9 sbkt
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-1
EX-10.14
vj1v35r7
26 Feb 21
Registration statement (foreign)
4:56pm
20-F
EX-4.11
ba3gehsf 73
31 Mar 22
Annual report (foreign)
4:33pm
F-1/A
y746oai56 efb
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
F-1/A
7hygtl30
18 Mar 21
Registration statement (foreign) (amended)
6:15am
DRS
34vaks2 gg1bnyourhz
17 Dec 20
Draft registration statement
12:00am
424B4
23zb dh3yo
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1
6cy1s h3m
26 Feb 21
Registration statement (foreign)
4:56pm
DRS/A
oqd5nhznh1fc to3
26 Jan 21
Draft registration statement (amended)
12:00am